Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline
2022 | journal article; research paper. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline
Emdina, A.; Hermann, P.; Varges, D.; Nuhn, S.; Goebel, S.; Bunck, T. & Maass, F. et al. (2022)
Diagnostics, 12(5) pp. 1259. DOI: https://doi.org/10.3390/diagnostics12051259
Documents & Media
Details
- Authors
- Emdina, Anna; Hermann, Peter; Varges, Daniela; Nuhn, Sabine; Goebel, Stefan; Bunck, Timothy; Maass, Fabian; Schmitz, Matthias; Llorens, Franc; Kruse, Niels; Zerr, Inga; Lingor, Paul; Mollenhauer, Brit
- Abstract
- Biomarkers are increasingly recognized as tools in the diagnosis and prognosis of neurodegenerative diseases. No fluid biomarker for Parkinson’s disease (PD) has been established to date, but α-synuclein, a major component of Lewy bodies in PD and dementia with Lewy bodies (DLB), has become a promising candidate. Here, we investigated CSF α-synuclein in patients with PD (n = 28), PDD (n = 8), and DLB (n = 5), applying an electrochemiluminescence immunoassay. Median values were non-significantly (p = 0.430) higher in patients with PDD and DLB (287 pg/mL) than in PD (236 pg/mL). A group of n = 36 primarily non-demented patients with PD and PDD was clinically followed for up to two years. A higher baseline α-synuclein was associated with increases in Hoehn and Yahr classifications (p = 0.019) and Beck Depression Inventory scores (p < 0.001) as well as worse performance in Trail Making Test A (p = 0.017), Trail Making Test B (p = 0.043), and the Boston Naming Test (p = 0.002) at follow-up. Surprisingly, higher levels were associated with a better performance in semantic verbal fluency tests (p = 0.046). In summary, CSF α-synuclein may be a potential prognostic marker for disease progression, affective symptoms, and executive cognitive function in PD. Larger-scaled studies have to validate these findings and the discordant results for single cognitive tests in this exploratory investigation.
- Issue Date
- 2022
- Journal
- Diagnostics
- eISSN
- 2075-4418
- Language
- English